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A Genomewide Linkage Study of 1,933 Families Affected by Premature
Coronary Artery Disease: The British Heart Foundation (BHF) Family
Heart Study
The BHF Family Heart Study Research Group*
Coronary artery disease (CAD) and its most important complication, myocardial infarction (MI), are the leading
cause of premature death in the Western world. CAD has a substantial genetic basis, especially when it occurs
early. We investigated the genetic determinants of premature CAD by performing a genomewide linkage analysis
of 4,175 affected subjects from 1,933 families recruited throughout the United Kingdom. Each family had at least
two available siblings with CAD, with validated onset before age 66 years. Linkage analysis was performed using
416 microsatellite markers. We observed suggestive linkage, for both CAD and MI, to a region on chromosome
2. For CAD, a LOD score of 1.86 was observed at marker D2S2271, which, in an ordered subset analysis, increased
to 2.70 in families ( ) with a minimum age at diagnosis of 56 years or younger. For MI, an overlappingnp 1,698
peak with a LOD score of 1.15 was observed at marker D2S2216, which increased to 2.1 in families ( )np 801
with a minimum age at diagnosis of 59 years or younger. Exclusion mapping showed that 100% of the autosomal
genome could be excluded for locus-speciﬁc sibling relative risks of 1.5 and 1.6 for CAD and MI, respectively. The
region identiﬁed on chromosome 2 overlaps linked regions observed in two other smaller genome scans for CAD.
Together, these ﬁndings strongly suggest that there is a locus on chromosome 2 that inﬂuences coronary athero-
sclerosis risk. The exclusion of a common locus that increases risk of CAD to siblings by 150% has important
implications for strategies for further deﬁning the genetic basis of CAD.
Introduction
Atherosclerotic coronary artery disease (CAD) and its
most important complication, acutemyocardial infarction
(MI), are the most common cause of premature death
and morbidity in the Western world. In addition to well-
recognized lifestyle risk factors, genetic factors play a
key role in the pathogenesis of CAD, particularly early-
onset CAD. First-degree relatives of patients who have
had an acute MI prior to age 55 years have 2–7 times
the risk that their peers have (Lusis et al. 2004). Fur-
thermore, twin studies indicate an eightfold increase in
risk of death from an MI if a ﬁrst twin dies of an MI
before age 55 years (Marenberg et al. 1994).
With use of a case-control approach, variants in many
candidate genes have been investigated for their effects
on risks of CAD and MI. Polymorphisms in genes en-
coding proteins involved in lipid metabolism, thrombo-
sis, and vascular biology, among others, have been as-
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sociated with increased risk of CAD and/or MI in cer-
tain populations (Topol et al. 2001; Ozaki et al. 2002,
2004; Yamada et al. 2002; Lusis et al. 2004). However,
many of the ﬁndings made with this approach require
independent veriﬁcation and identiﬁcation of the func-
tional basis of the association. At the same time, a num-
ber of genomewide linkage scans—mainly of affected
sib pairs—to map CAD and/or MI loci have also been
attempted (Pajukanta et al. 2000; Francke et al. 2001;
Broeckel et al. 2002; Harrap et al. 2002; Hauser et al.
2004a; Helgadottir et al. 2004;Wang et al. 2004). These
have suggested the presence of such loci on chromo-
somes 1, 2, 3, 12, 13, 14, 16, and X. However, in only
one case (chromosome 13) has the putative underlying
gene yet been identiﬁed (Helgadottir et al. 2004).
Taken together, the ﬁndings to date provide grounds
for belief that further analysis of the genetic basis of
CAD may provide novel insights into its pathogenesis,
improve risk stratiﬁcation of individuals, identify novel
targets for drug development, and inﬂuence treatment
strategies. The BHF Family Heart Study was conceived
primarily to provide a major resource of affected sib
pairs for mapping genes involved in the pathogenesis of
premature CAD through a linkage-based approach. The
1,933 families analyzed represent one of the largest col-
lections yet assembled for this purpose. Because of the
possibility that some loci may confer risk only for MI
rather than for CAD overall (Lusis et al. 2004; Wang
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et al. 2004) and that some may manifest their effect
only at a younger age, we prospectively speciﬁed addi-
tional analyses in relation to these groups. Here, we re-
port the BHF Family Heart Study results for these main
analyses of the initial genome scan.
Subjects and Methods
Recruitment
The objective of the BHF Family Heart Study was to
establish a substantial resource of families with at least
two siblings affected with premature CAD, deﬁned as
“the occurrence of MI or angina (veriﬁed by exercise
stress test or angiography) or the need for coronary ar-
tery bypass surgery (CABG) or percutaneous translumi-
nal coronary angioplasty (PTCA) before the 66th birth-
day.” Recruitment was performed on a national basis in
the United Kingdom (UK) through (1) a direct appeal
to the public via the media and (2) mailing all general
practices (family physicians) in the UK with information
about the study. In an initial pilot phase, potential par-
ticipants were also identiﬁed and approached through
local CAD databases at the two lead centers (Leeds and
Leicester). Interested subjects could register in the study
either through a Freephone or Freepost basis. An attempt
was made to include all available affected siblings of
participating families. Unaffected siblings were also re-
cruited, if available, but are not included in the present
analysis. In total, we collected 6,285 subjects. After val-
idation, 4,216 individuals from 1,958 families were ge-
notyped, and the ﬁnal analysis included 4,175 affected
subjects from 1,933 families (see the “Results” section).
The study was approved by the Yorkshire Multicentre
Research Ethics Committee and by 206 local research
ethics committees across the UK. Subjects provided writ-
ten informed consent, and the study was performed un-
der the principles of the Declaration of Helsinki and com-
plied with UK legislation for data protection.
Data Collection, Validation, and Handling
After a preliminary screen to establish suitability, par-
ticipating members of families that met the criteria for
the study were interviewed by telephone by a trained
nurse using a standardized questionnaire. Information
obtained included personal and family history of CAD,
including the nature and time of ﬁrst and any subsequent
events, and information about risk-factor proﬁle. Ar-
rangements were made, usually via the general practi-
tioner (GP), to obtain a blood sample for DNA. For
each subject, independent veriﬁcation of history of CAD
was obtained either via direct examination of hospital
records or via the GP; only subjects for whom such ver-
iﬁcation could be obtained were included in the study.
All clinical data were stored on a Microsoft SQL server
relational database speciﬁcally designed for the study.
Each subject was given a unique identity number and only
anonymized clinical data were merged with the genotype
data for analysis.
DNA Extraction and Genotyping
Leukocyte DNA was extracted from 18 ml of blood
collected in EDTA with use of the PURGENE_DNA Ex-
traction Kits (Gentra Systems) andwas quantiﬁed by spec-
trophotometry. In the ﬁrst phase of the genome scan,
398 of 400 microsatellite markers from the ABI-Prism
Linkage Mapping set v2.5-MD10 (Applied Biosystems)
spaced at ∼10 cM were typed. For technical reasons,
two markers from the set, D14S68 and D6S434, were
not typed. PCR was performed, using 10 ng of DNA
per reaction, under conditions described by the manu-
facturers, and the products were pooled in panels and
were analyzed on ABI-Prism 3700 DNA sequencers. Ge-
notypes from each marker were examined by the Gene-
Mapper software v 2.0 (Applied Biosystems). In the sec-
ond phase, a further 18 markers (D1S2850, D3S3609,
D3S3706, D5S1960, D6S282, D6S1671, D8S543,
D8S1705, D11S4190, D12S313, D12S1725,D14S1044,
D17SS927, D18S465, D18S1127, DXS1055, DXS1061,
and DXS1062) were genotyped, to close any gaps 119
cM. These markers were selected fromABI-PrismLinkage
Mapping set v2.5-HD5. Finally, an additional eightmark-
ers (D2S139, D2S2264, D2S293, D2S2329, D2S2271,
D2S2215, D2S1326, and D2S2241) were typed, to in-
vestigate and reﬁne the linkage region observed on chro-
mosome 2.
Quality Control of Genotype Data
All genotypes, including those that passed GeneMap-
per’s internal quality control, were manually read by at
least one individual, and those genotypes that did not
fully pass the program’s quality control were read in-
dependently by two individuals. Genotypeswere rejected
and the samples rerun if there was not complete agree-
ment on allele calls. The Graphical Representation of
Relationship (Abecasis et al. 2001) and RELATIVE (Gor-
ing and Ott 1997) programs were used to conﬁrm fami-
ly relationships. Genotypes inconsistent with Mendelian
laws were detected using the PedCheck program (O’Con-
nell and Weeks 1998). Those genotypes were reexam-
ined, were corrected if obviously incorrect, or were de-
leted. Absence of parental data meant that such errors
were detectable only in larger sibships, so unlikely geno-
types were also identiﬁed using Merlin (Abecasis et al.
2002). When these “unlikely” genotypes were reexam-
ined, clear errors were corrected and uncertain genotypes
were deleted, but genotypes that appeared correct on
reexamination were left unchanged. The mean propor-
tion of alleles per marker taken to analysis was 96.0%
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(a range of 90.2%–99.4%), and the mean information
content across all loci assessed in the genome scan was
64% (38%–84%).
Linkage Analysis
Recombination fractions between markers were esti-
mated from CEPH (Dib et al. 1996) and deCode (Kong
et al. 2002) genotype data by use of the CRI-MAP pro-
gram (Lander and Green 1987) and were implemented
in MAP-O-MAT (Kong et al. 2004; Kong and Matise
2005), under licensed agreement with deCODE. Maxi-
mum-likelihood estimates of marker-allele frequencies
were obtained using MENDEL v5.5 (Lange et al. 2001).
This method uses genotype data from all individuals and
takes their genetic relationships into account. Genome-
wide nonparametric multipoint linkage analysis was per-
formed using the Allegro program (Gudbjartsson et al.
2000). LOD scores were calculated on the basis of the
exponential model of Kong and Cox (1997). This LOD
score was chosen because, in cases for which the inher-
itance information is incomplete, it does not have the
conservative properties of the nonparametric linkage
(NPL) score implemented in Genehunter (Kruglyak et al.
1996). The SALL statistic (Whittemore and Halpern
1994), which captures the identity-by-descent–sharing
information in a family, was used to calculate the LOD
score. SALL considers the family as a whole and gives
extra weight if the same allele is shared between different
pairs of relatives.
For the CAD phenotype, all families were included
in the analysis. For the MI phenotype, analysis was re-
stricted to those families with at least two individuals
with a conﬁrmed MI.
Reported P values are estimates of pointwise signiﬁ-
cance that are based on the theoretical distribution of
the statistic, provided by Allegro (Kong et al. 2004). In
addition, genomewide signiﬁcance was assessed by sim-
ulating data under the null hypothesis of no linkage with
the observed pedigree structure and marker character-
istics (including the pattern of missing genotype data).
One thousand such data sets were simulated using the
program Merlin (Abecasis et al. 2002) and then were
analyzed using the Kong and Cox (1997) LOD score.
Genomewide signiﬁcance was estimated by the propor-
tion of times that a particular LOD score was reached
anywhere in the genome.
Analysis for Age Effect
Ordered subset linkage analysis (OSA) (Hauser et al.
2004b) was employed for consideration of age at diag-
nosis. The OSA groups families into subsets on the basis
of the value of a covariate—in this case, the minimum
age at diagnosis in each family. In each subset, all fam-
ilies in which the minimum age is below a certain value
are included. Therefore, as the age increases, the size
of the subset also increases. Linkage analysis was per-
formed for each subset, and the maximum LOD score
on each chromosome across all subsets was reported.
OSA has been used elsewhere as a test for the effect of
a covariate (such as age at onset) on linkage, conditional
on overall linkage (Hauser et al. 2004b). Our aim was
to use this method differently, to test for linkage, possi-
bly conﬁned to a subset deﬁned by young age at onset,
against the null hypothesis of no linkage. For this rea-
son, we assessed the chromosomewide signiﬁcance of
our ﬁndings by conducting simulations in which we ex-
amined how often observed LOD scores were exceeded
anywhere on the same chromosome in any subset de-
ﬁned by ordering on the covariate. In each simulation,
the pedigree structures and ages at onset were ﬁxed, but
genotypes were assigned according to the null hypothesis
of no linkage (so there was no conditioning on the ob-
served linkage signal).
Exclusion Mapping
In addition to the linkage analysis, exclusion mapping
was performed for a number of different values of ls
(the sibling relative risk) and an exclusion criterion of
, to exclude genomic regions unlikely to har-LOD ! 2
bor loci contributing to various levels of CAD or MI
risk. This was performed for all 22 autosome pairs, with
use of GENEHUNTER (Kruglyak et al. 1996), with use
of one sibling pair from each family.
Results
Subjects
In total, we collected 6,285 subjects. After validation,
4,216 individuals from 1,958 families were genotyped.
We identiﬁed 100 half-sibling pairs, 16 identical pairs
(MZ twins or sample duplications), 11 individuals with
incorrectly speciﬁed sex, and 16 families with unrelated
pairs of individuals, presumably because of sample swaps
or adoption. Half siblings in 93 sibships were included
in the analysis after correct speciﬁcation of the relation-
ship. Other relationships were corrected when possible;
otherwise, the individuals were removed from subsequent
analyses. In the ﬁnal analysis, we included 4,175 affected
subjects from 1,933 families: 1,675 affected sibling pairs,
220 affected trios, and 38 sibships or extended families
with more than three affected individuals.
The demographics of the families and individuals an-
alyzed are shown in table 1. There was a 3:1 ratio of
males:females. The mean age (SD) at the ﬁrst vali-
dated evidence of CAD was 51.7 (7.7) years for men
and 54.1 (7.3) years for women ( ). The meanP ! .001
age at time of the study was 61.0 (7.0) years. Of the
subjects, 2,556 (61.2%) had suffered an MI. A majority
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Table 1
BHF Family Heart Study Population Characteristics
CHARACTERISTIC
FINDINGS FOR SUBJECTS WITH
CAD Phenotype MI Subphenotype
No. of study families 1,933 847
No. of affected individuals 4,175 1,776
Percentage of affected males/females 73.8/26.2 77.2/22.8
Mean age, in years (SD), at onset for affected males 51.7 (7.7) 50.7 (7.9)
Mean age, in years (SD), at onset for affected females 54.1 (7.4) 53.4 (7.8)
Mean age, in years (SD), at exam for affected individuals 61.0 (7.4) 61.6 (7.8)
Percentages of subjects, by ethnicity (European/Asian/other) 98.5/1.4 /.1 98.6/1.2/.1
No. (%) of validated and analyzed families, by number of affected siblings:
Two 1,675 (86.5) 772 (91.1)
Three 220 (11.4) 69 (8.1)
More than three 38 (2.0) 6 (.8)
No. (%) of subjects affected at age !66 years:
With MI with revascularization (percutaneous coronary intervention/CABG) 1,365 (32.7) 937 (52.8)
With MI without revascularization 1,191 (28.5) 839 (47.2)
No. (%) of subjects affected by CAD but not MI at age !66 years:
CAD with revascularization (percutaneous coronary intervention/CABG) 1,161 (27.8) …
CAD (angiography or exercise stress test) without revascularization 458 (11.0) …
No. (%) of subjects with parental history of CAD at age !66 years:
Neither parent affected 774 (40.1) 343 (40.4)
Father affected 617 (31.9) 260 (30.7)
Mother affected 320 (16.6) 146 (17.2)
Both affected 221 (11.4) 98 (11.6)
No. (%) of subjects with cardiovascular risk factors:
Smoking history 3,051 (73.1) 1,355 (76.3)
Diabetes mellitus (receiving treatment) 490 (11.7) 151 (11.8)
Hypertension (receiving treatment) 1,924 (46.1) 789 (44.4)
Hyperlipidemia (15.0 mmol/liter or receiving treatment) 3,384 (81.1) 1,415 (79.7)
Obesity (BMI 125 kg/m2) 3,018 (72.3) 1,283 (72.2)
(60.5%) had also had a revascularization procedure. As
expected, the major coronary risk factors were com-
monly present, and the majority of subjects had multiple
risk factors (table 1). A majority (60%) of the subjects
had a family history (one or both parents) of premature
CAD. On the basis of self-reported ethnicity, 98.5% of
subjects were of European origin.
Results of Genome Scans for CAD and MI
The results of the multipoint 10-cM genome scan for
the whole population with CAD ( families)np 1,933
and for the families with only the MI phenotype (np
) are summarized in ﬁgure 1. For each phenotype,847
we found a single LOD score 11.0—on chromosome 2
(see below). Other loci with LOD scores of 0.5–1.0 were
observed for the CAD phenotype on chromosomes 2, 5,
6, 8, and 14 and for the MI phenotype on chromosomes
1, 2, 4, 5, 6, 10, 12, 16, 18, 19, and X (ﬁg. 1 and table
2). None of the results were statistically signiﬁcant at the
genomewide level.
Chromosome 2
Figure 2 shows in detail the results for the main peaks
on chromosome 2. The peak LOD score for the CAD
phenotype was between neighboring markers D2S347
and D2S112, with a LOD score of 1.98 (pointwise
). In simulation studies, a maximum LODPp .0014
score of 1.98 was found in 310/1,000 analyses of data
simulated under the null hypothesis of no linkage, for a
genomewide P value of .31. With inclusion of the extra
markers, the LOD fell slightly to 1.86 (pointwise Pp
) at marker D2S2271, which lies between the two.0021
previous ﬂanking markers. For MI, the peak multipoint
LOD score was at marker D2S2216, with a LOD score
of 1.48 (pointwise ) (ﬁg. 2), falling to 1.15Pp .0046
(pointwise ) with the addition of the extraPp .011
markers.
Effect of Age at Onset
The OSA for CAD had a LOD score of 2.70 on chro-
mosome 2 at the same location as in the overall analy-
sis of families with a minimum age at diagnosis of 56
years (ﬁg. 2). There were 1,698 families in this subgroup.
For MI, a peak LOD score of 2.1 was found, again at
marker D2S2216, in 801 families with a minimum age
at diagnosis of 59 years.
Other loci identiﬁed from OSA for CAD included a
LOD of 3.42 between ﬂanking markers D9S175 and
D9S167 on chromosome 9. However, the subset was
small, with only 16 families with at least one individual
BHF Family Heart Study Research Group: Linkage Analysis of Premature CAD 1015
Figure 1 Summary of results of linkage analysis for CAD (upper panel) and MI (lower panel). The peaks and corresponding LOD scores
obtained for each chromosome from the multipoint linkage analysis of the initial genome scan ( markers) are shown.np 398
with an age at diagnosis of 30 years. A LOD score of
3.24 was also seen between D17S787 and D17S944 on
chromosome 17. Again, this was in a small subset of 26
families with at least one individual with an age at diag-
nosis of 31 years. OSA also identiﬁed (1) a locus for
MI, with a LOD score of 2.4 between markers D5S630
and D5S416 on chromosome 5, in a subset of 205 fam-
ilies with at least one individual with an age at diagnosis
of 42 years and (2) a locus for MI on the X chromo-
some with a LOD score of 2.4 between markersDXS991
and DXS986 in a subset of 232 families with at least
one individual with an age at diagnosis of 43 years.
Chromosomewide P values were estimated to be .08 for
chromosome 2, .006 for chromosome 9, and .01 for
chromosome 17. The results for chromosomes 9 and 17
are thus signiﬁcant at the chromosomewide but not ge-
nomewide level.
Exclusion Mapping
The results of exclusion mapping for CAD and MI
(the full length of the map used was 3,747.4 cM) for
this population showed that, for CAD, 100% of the
autosomal genome could be excluded for a locus-speciﬁc
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Table 2
Summary of the LOD Scores 1.5 for CAD and MI
Phenotype
Chromosome,
and Position
(cM) Nearest Marker(s) LOD Pointwise P
CADa:
2:
149 D2S347–D2S112 1.9819 .001449
274.5 D2S338–D2S125 .7275 .03886
5:
207.6 D5S400–D5S1960 .8709 .0278
6:
22.2 D6S289 .9125 .025396
182.8 D6S1581–D6S264 .5304 .0636
8:
124.8 D8S1784 .6639 .0455
14:
70.0 D14S63–D14S258 .6159 .05125
36.5 D14S70 .5194 .0655
MI:
1:
118.8 D1S2841 .7266 .033095
2:
119.3 D2S2216 1.4814 .0046
4:
0 D4S412 .5167 .0602
40.6 D4S419 .6002 .046941
5:
27.4 D5S630 .5254 .058574
6:
182.8 D6S1581–D6S264 .8529 .023688
10:
174.7 D10S587–D10S217 .7187 .0338
12:
157.0 D12S86 .8932 .02136
16:
40.3 D16S3068 .7794 .0287
18:
93.8 D18S64 .514 .0606
19:
89.6 D19S571–D19S418 .6889 .0366
X:
0 DXS106 .5171 .0613
155.3 DXS1062 .6049 .0475
NOTE.—For each region, the position of the maximum LOD score
is listed. The position is the distance from the most telomeric marker
genotyped (set to 0 cM). The pointwise P values are derived from the
theoretical distribution of the LOD score under the null hypothesis.
a Includes MI.
ls of 1.5 and, for MI, because of the smaller sample size,
100% of the autosomal genome could be excluded only
for a ls of 1.6. For CAD, the entire genome, apart from
a region surrounding the peak on chromosome 2, could
be excluded, for a ls of 1.4; this represents 99.6% of
the autosomal genome. For a ls of 1.3, 98.8% of the
genome was excluded, dropping to 95.6% for a ls of
1.25. Although 86.1% of the genome is excluded for a
ls of 1.2, there remain regions on most chromosomes
that could harbor disease genes with this size of effect.
Discussion
Identiﬁcation of genetic factors that predispose to CAD
and understanding their interactions with environmental
risk factors has the potential to identify of novel thera-
peutic targets, to improve risk stratiﬁcation of individ-
uals, and to allow better tailoring of preventive and treat-
ment options. In this study, we report the largest genome
scan to date, investigating the genetic basis of CAD and
MI in a cohort of subjects with a risk-factor proﬁle typ-
ical of patients with premature CAD (Yusuf et al. 2004).
Our results are consistent with the complex genetic eti-
ology of CAD and suggest that there is either no single
locus or a small number of major loci that explain the
familial risk of these diseases.
Our most interesting ﬁnding was on chromosome 2,
where we observed suggestive linkage for both CAD and
MI. Several observations suggest that these observed
linkages are informative, despite LOD scores that do
not reach genomewide signiﬁcance. Both CAD and MI
mapped to the same site, and the peaks persisted, with
slightly reduced LOD scores, when additional markers
in the region were genotyped. The fact that the peak
locations of the linkages for CAD and MI were slightly
displaced from each other should not be considered an
indication of the presence of separate loci for the two
conditions. Simulation studies have shown that there is
considerable imprecision in the location of peaks in link-
age studies, and it is more likely that this explains the
lack of coincidence (Roberts et al. 1999). Furthermore,
the peaks for both CAD and MI (ﬁg. 2) increased when
analysis was restricted to families with earlier onset of
disease, consistent with the observation that the genetic
contribution to CAD and MI is likely to be more im-
portant in early disease. Importantly, there is concor-
dance of our ﬁndings on chromosome 2 with two other
genome scans related to atherosclerotic coronary dis-
ease. Wang et al. (2004), in a study of 928 families,
reported a LOD score of 3.82 at the same locus in a
U.S. cohort characterized by familial premature CAD
and MI, although that was not their major peak. More
strikingly, the linkage observed with CAD to 2q21.1-
22 in a genetically isolated Finnish population of 156
families (Pajukanta et al. 2000) is very close to our
region. Interestingly, a genomewide linkage study con-
ducted by Fox et al. (2004) to localize QTLs inﬂuencing
carotid intima-media thickness, a marker of atheroscle-
rosis, revealed a LOD score of 1.57 at marker D2S1790
(103 cM). These ﬁndings, taken together, strongly sug-
gest that there is a locus inﬂuencing coronary athero-
sclerosis risk in this region of chromosome 2. However,
it should be noted that our main locus of interest does
not overlap with that of another genome scan that re-
ported suggestive linkage to chromosome 2 for acute
coronary syndrome (Harrap et al. 2002).
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Figure 2 More-detailed representation of the linkages observed on chromosome 2 from the initial genome scan. The solid line represents
the main CAD phenotype; the long-dashed line represents the MI subphenotype; the short-dashed line represent the CAD phenotype for families
with minimum age at onset of !56 years.
Genome scans of the type undertaken here have also
reported signiﬁcant linkages to CAD and/or MI for chro-
mosomes 1p34-36 (Wang et al. 2004), 1q25 (Hauser et
al. 2004a), 3q (Hauser et al. 2004a), 14q (Broeckel et
al. 2002), and 16p13-pter (Francke et al. 2001). Despite
the much larger size of our study, we have not replicated
those results. There are several potential explanations.
First, it is notable that the different scans published
elsewhere also vary in the loci identiﬁed, with little rep-
lication between them. Although the linkages described
reach genomewide signiﬁcance, this should be inter-
preted with caution, since some could still be false-pos-
itive results. However, there could also be genuine dif-
ferences between populations. Although the majority of
our subjects were of European origin, it is conceivable
that they represent a more heterogeneous group than
did subjects of some of the other studies. Differences in
classiﬁcation of endpoints or genotyping approaches
seem unlikely sources of discrepancy. Our deﬁnitions of
CAD and MI were standard and were veriﬁed in all
subjects by direct assessment of patient records. Geno-
typing was performed to a high degree of completeness,
and several checks were employed (see the “Subjects
and Methods” section) to ensure accuracy. There are
some variations in the precise statistical tests used. We
used the extension to the NPL statistic that was pro-
posed by Kong and Cox (1997), which tests for excess
sharing of alleles among the set of affected relatives
within a family. This test has been shown to compare
well with other methods, which can be biased toward
the null hypothesis (Cordell 2004).
It was somewhat surprising that we found neither dis-
tinct nor stronger linkages to MI, given the more precise
deﬁnition of this phenotype (Samani 1998) and the ﬁnd-
ings of some previous studies, in which linkages were
observed only for MI and not for CAD (Wang et al.
2004). This is despite the fact that even with the reduced
number of families for the MI phenotype, our study is
still one of the largest that has investigated this pheno-
type. Although the presence of coronary atherosclerosis
provides the main substrate for the development of MI,
other factors, including thrombotic potential, inﬂuence
the risk of MI, and it is not entirely unexpected that
speciﬁc loci could inﬂuence the risk of each phenotype.
That said, it is interesting to note that both CAD and
MI mapped to the same locus in our study, which sug-
gests that, if a common gene is involved, it affects path-
ways that inﬂuence the risk of both phenotypes.
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The genetic inﬂuence on CAD is more apparent the
earlier the disease onset, although the relationship is not
necessarily linear and may vary from locus to locus.
Several approaches can be used to look for genetic loci
that inﬂuence the risk of more-premature disease. In this
study, we used the OSA method recently described by
Hauser et al. (2004b). The approach is valuable in that
it does not deﬁne any arbitrary “age cutoff” to look for
an effect; instead, it maximizes the use of data and al-
lows modeling of age effect for each locus. Our analysis
strengthened the ﬁndings on chromosome 2 and sug-
gests that this locus especially predisposes to disease in
subjects aged !56 years. However, it should be noted
that the peak LOD score of 2.70 in this analysis also
did not reach genomewide signiﬁcance in simulation
studies. OSA also identiﬁed a number of other potential
loci. Of particular interest is the observation of a locus
on chromosome X linked to MI where another study
has also reported linkage (Pajukanta et al. 2000). The
ﬁndings on chromosomes 9 and 17, for which the results
relate to only a small number of families, need to be
treated with appropriate caution. However, the recent
report (Wang et al. 2003) of a possibly monogenic form
of early-onset CAD does indicate that some families
may harbor mutations of this type. Although an initial
examination of these families does not identify any ob-
vious distinguishing clinical features, a more detailed
evaluation of the linkages in these families would seem
worthwhile.
Our ﬁndings raise several issues about the genome-
wide-linkage approach to common complex diseases
such as CAD. The presence of genetic heterogeneity is
clearly an important limitation and the most likely ex-
planation for our failure to ﬁnd signiﬁcant linkages de-
spite the comparatively large size of our study. Our an-
alyses of subjects with MI and the use of age as a cri-
terion were attempts to address this issue. With use of
even more narrowly deﬁned phenotypes, less genetical-
ly heterogeneous groups could be identiﬁed, but any
choice should be based on strong biological plausibility.
For CAD, other risk factors and variables, such as smok-
ing history, dyslipidemia, and BMI, could be used to try
to deﬁne more-homogeneous groups and will be the
subject of further analysis of our data.
An immediate challenge posed by our ﬁndings is de-
termination of the best approach for further interroga-
tion of the locus on chromosome 2. The locus, encom-
passing both the MI and CAD peaks, spans ∼80 Mb
and contains 446 putative genes, many of which are
poorly characterized. However, there are several attrac-
tive potential candidate genes with cardiovascular ef-
fects. These include, for example, the interleukins 1A
and 1B clusters and protein C. Interleukin 1B polymor-
phisms have recently been found to associate with risk
of premature MI (Iacoviello et al. 2005). Apart from
analysis of obvious candidates, the systematic typing of
SNPs at regular intervals could narrow the region of
interest. This approach led to the identiﬁcation of the
5′-lipoxygenase activating protein (FLAP) as the likely
gene on chromosome 13 that confers risk of MI and
stroke (Helgadottir et al. 2004). Of note is that the peak
LOD score of 2.48 observed in the initial genome scan
in the study by Helgadottir et al. (2004) was also only
suggestive of linkage.
Genome scans with polymorphic markers in affected
families have the inherent advantage of allowing a non-
biased search for disease-causing loci. However, they
have lower power than case-control association studies.
Until recently, genome scans provided a complementary
approach to candidate-gene association studies. The in-
creasing identiﬁcation of SNPs and availability of high-
throughput SNP-typing platforms has opened the pos-
sibility of undertaking genomewide association studies
(Hinds et al. 2005), which makes the previous advan-
tage of genomewide linkage scans less certain. However,
even for such association studies, the key issues of ac-
curate phenotype and genetic risk remain. In this regard,
the BHF Family Heart Study has signiﬁcant advantages,
not only because of its size but also because of its se-
lection of subjects enriched for genetic risk of CAD.
In summary, we describe the assembly of a large re-
source of families with premature CAD for identiﬁca-
tion of genetic factors that predispose to this major dis-
ease. We report the results of our initial genome scan
and mapping of a locus for both CAD and MI, with
suggestive linkage to chromosome 2p12-2q23.3.
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